| aMSCs | Animal Mesenchymal Stem/Stromal Cells; |
| ATMPs | Advanced Therapies Medicinal Products; |
| bFBF | Basic fibroblast growth factors |
| CCR | Chemokine receptors |
| CM | Conditioned medium |
| CD | Cluster of differentiation |
| COX2 | Cyclooxygenase 2 |
| CXCL | Chemokine ligand |
| CXCR | Chemokine receptors |
| DC | Dendritic Cells; |
| EGF | Epidermal Growth Factor |
| EMA | European Medicine Agency; |
| EV | Extracellular Vesicles |
| FasL | Fas Ligand |
| FDA | Food and Drug Administration; |
| FGFR | Fibroblast growth factor receptors |
| HCAM | Homing Cell Adhesion Molecule |
| HCT/Ps | Human Cellular and Tissue-based Products; |
| HGF | Hepatocyte growth Factor |
| HLA | Human Leucocyte Antigen |
| HLA-G | Human Leucocyte Antigen G; |
| hMSCs | Human Mesenchymal Stem/Stromal Cells; |
| ICAM | Intercellular Adhesion Molecule |
| IDO | Indoleamine 2, 3-dioxygenase |
| IFN | Interferon |
| IGF | insulin-like growth factor |
| IL | Interleukin |
| iNOS | Inducible nitric oxide synthase |
| ISCT | International Society for Cellular Therapy |
| KGF | Keratinocyte Growth Factor |
| LPS | Lipopolysaccharides |
| miRNA | MicroRNA |
| MMP | Metalloproteinases |
| MSCs | Mesenchymal Stem/Stromal Cells; |
| NK | Natural Killers; |
| NO | Nitric oxide |
| PCL | Phospholipase |
| PDGF | Platelet-derived growth factor |
| PD-L | Programmed death-ligand |
| PD | Programmed death |
| PGE | Prostaglandins E |
| PSGL | P-selectin glycoprotein ligand |
| ROS | Reactive Oxygen Species |
| SDF | Stromal cell-derived factor |
| TGF | Transforming Growth Factor |
| TGF | Transforming Growth Factor |
| TIMP | Tissue inhibitors of metalloproteinases |
| TLR | Toll-like receptors |
| TNF | Tumor Necrosis Factor |
| Treg | Regulatory T Lymphocytes |
| VCAM | Vascular Cell Adhesion Molecule |
| VEGF | Endothelial growth factor |
| VLA | Very Late Antigen |